Cargando…
Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy
PURPOSE: To evaluate the effectiveness of incobotulinumtoxinA (Xeomin(®)) in treating upper eyelid retraction in patients with Graves orbitopathy (GO) initially scheduled for surgery via two different application sites. METHODS: This is a comparative, prospective study, conducted at the Department o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805617/ https://www.ncbi.nlm.nih.gov/pubmed/36587368 http://dx.doi.org/10.1007/s10792-022-02625-7 |
_version_ | 1784862367316705280 |
---|---|
author | Vokurka Topljak, Sandra Galiot Delić, Martina Mandić, Krešimir Perić, Sanja Baretić, Maja Juri Mandić, Jelena |
author_facet | Vokurka Topljak, Sandra Galiot Delić, Martina Mandić, Krešimir Perić, Sanja Baretić, Maja Juri Mandić, Jelena |
author_sort | Vokurka Topljak, Sandra |
collection | PubMed |
description | PURPOSE: To evaluate the effectiveness of incobotulinumtoxinA (Xeomin(®)) in treating upper eyelid retraction in patients with Graves orbitopathy (GO) initially scheduled for surgery via two different application sites. METHODS: This is a comparative, prospective study, conducted at the Department of Ophthalmology, Medical School, University Hospital Centre Zagreb, EUGOGO site (EUropean Group On Graves' Orbitopathy) in Croatia from January 2020 till January of 2021 in accordance with national health headquarter recommendations. All patients were classified as inactive with marked eyelid retraction and randomly divided into groups according to application sites. Group A underwent transconjunctival application (18 eyes) and group B transcutaneous application (20 eyes) of incobotulinumtoxinA. The primary end point of this study was lowering the eyelid, to alleviate anterior eye segment symptoms and achieve acceptable aesthetic appearance until surgery becomes available. RESULTS: There were no nonresponders and we found no statistically significant difference in the degree of lowering the eyelid between the two application sites. Following rules for avoiding spread of SARS-CoV-19, none of the patients included in this study were infected. Moreover, participants reported diminishing of anterior eye segment irritation and improved aesthetics. CONCLUSION: Treatment of inactive GO patients with incobotulinumtoxinA for upper eyelid retraction is efficient and safe and can be used as an adjuvant treatment while patients wait for surgery, by alleviating symptoms and improving the level of aesthetic satisfaction without causing a threat to anterior eye segment and visual function. The study showed that effect of treatment was the same, whether we applied the toxin transconjunctivaly or transcutaneously. |
format | Online Article Text |
id | pubmed-9805617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-98056172023-01-04 Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy Vokurka Topljak, Sandra Galiot Delić, Martina Mandić, Krešimir Perić, Sanja Baretić, Maja Juri Mandić, Jelena Int Ophthalmol Original Paper PURPOSE: To evaluate the effectiveness of incobotulinumtoxinA (Xeomin(®)) in treating upper eyelid retraction in patients with Graves orbitopathy (GO) initially scheduled for surgery via two different application sites. METHODS: This is a comparative, prospective study, conducted at the Department of Ophthalmology, Medical School, University Hospital Centre Zagreb, EUGOGO site (EUropean Group On Graves' Orbitopathy) in Croatia from January 2020 till January of 2021 in accordance with national health headquarter recommendations. All patients were classified as inactive with marked eyelid retraction and randomly divided into groups according to application sites. Group A underwent transconjunctival application (18 eyes) and group B transcutaneous application (20 eyes) of incobotulinumtoxinA. The primary end point of this study was lowering the eyelid, to alleviate anterior eye segment symptoms and achieve acceptable aesthetic appearance until surgery becomes available. RESULTS: There were no nonresponders and we found no statistically significant difference in the degree of lowering the eyelid between the two application sites. Following rules for avoiding spread of SARS-CoV-19, none of the patients included in this study were infected. Moreover, participants reported diminishing of anterior eye segment irritation and improved aesthetics. CONCLUSION: Treatment of inactive GO patients with incobotulinumtoxinA for upper eyelid retraction is efficient and safe and can be used as an adjuvant treatment while patients wait for surgery, by alleviating symptoms and improving the level of aesthetic satisfaction without causing a threat to anterior eye segment and visual function. The study showed that effect of treatment was the same, whether we applied the toxin transconjunctivaly or transcutaneously. Springer Netherlands 2023-01-01 /pmc/articles/PMC9805617/ /pubmed/36587368 http://dx.doi.org/10.1007/s10792-022-02625-7 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper Vokurka Topljak, Sandra Galiot Delić, Martina Mandić, Krešimir Perić, Sanja Baretić, Maja Juri Mandić, Jelena Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy |
title | Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy |
title_full | Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy |
title_fullStr | Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy |
title_full_unstemmed | Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy |
title_short | Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy |
title_sort | nonsurgical treatment for upper eyelid retraction in patients with inactive graves’ orbitopathy |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805617/ https://www.ncbi.nlm.nih.gov/pubmed/36587368 http://dx.doi.org/10.1007/s10792-022-02625-7 |
work_keys_str_mv | AT vokurkatopljaksandra nonsurgicaltreatmentforuppereyelidretractioninpatientswithinactivegravesorbitopathy AT galiotdelicmartina nonsurgicaltreatmentforuppereyelidretractioninpatientswithinactivegravesorbitopathy AT mandickresimir nonsurgicaltreatmentforuppereyelidretractioninpatientswithinactivegravesorbitopathy AT pericsanja nonsurgicaltreatmentforuppereyelidretractioninpatientswithinactivegravesorbitopathy AT bareticmaja nonsurgicaltreatmentforuppereyelidretractioninpatientswithinactivegravesorbitopathy AT jurimandicjelena nonsurgicaltreatmentforuppereyelidretractioninpatientswithinactivegravesorbitopathy |